{"url":"https://newsforagent.com/news/2026-11-12/viatris-nashik-hit-pacira-deal","markdown_url":"https://newsforagent.com/news/2026-11-12/viatris-nashik-hit-pacira-deal.md","title":"Viatris Sees $100 Million Hit as Generics Sales Stall","headline":"Viatris Books $100 Million Nashik Hit as It Looks to Pacira Deal for Growth","description":"Viatris took a $100 million sales hit from its suspended Nashik plant in Q3 and is counting on its pending $1.65 billion Pacira acquisition to lift growth.","section":"Earnings & Results","published_at":"2026-11-12T12:14:58+00:00","modified_at":"2026-11-12T12:14:58+00:00","author":"News Desk","key_takeaways":["Viatris absorbed a $100 million sales hit in the third quarter from the manufacturing suspension at its Nashik plant in India.","Viatris agreed in October 2026 to acquire Pacira BioSciences for $1.65 billion.","Viatris announced a 10% global workforce reduction, up to 3,000 employees, expected to generate $600-700 million in annual savings."],"companies":[{"name":"Viatris","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0003txe/viatris","website":"https://www.viatris.com/en"},{"name":"Pacira Pharmaceuticals","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0002kug/pacira-pharmaceuticals","website":"http://www.pacira.com"}],"source":{"publisher":"In Vivo","title":"Viatris Looks Ahead To Pacira Benefits As Generics Slide In Q3","url":"https://insights.citeline.com/generics-bulletin/business/earnings/viatris-looks-ahead-to-pacira-benefits-as-generics-slide-in-q3-FWWGXKKETNCBVBVQS3S4Y5BH7Q/"},"other_sources":[],"tags":["Earnings & Results","Viatris","Pacira Pharmaceuticals"],"body_markdown":"Viatris reported flat third-quarter generics sales, with a $100 million hit from the suspension of manufacturing at its Nashik plant in India, and said it expects benefits from its pending acquisition of Pacira BioSciences. [In Vivo](https://insights.citeline.com/generics-bulletin/business/earnings/viatris-looks-ahead-to-pacira-benefits-as-generics-slide-in-q3-FWWGXKKETNCBVBVQS3S4Y5BH7Q/) reported the results and the company's outlook.\n\n## Viatris Counts on Pacira as Nashik Weighs on Generics\n\n[Viatris](https://akta.pro/company-profiles/0003txe/viatris) is a global pharmaceutical company formed in 2020 from the merger of Mylan and Pfizer's Upjohn division, operating in more than 165 countries with generics, established brands and innovative medicines. The company said the Nashik suspension was the main drag on a flat quarter for generics turnover, and that it remains optimistic about its generics pipeline and the benefits it will gain from the Pacira deal.\n\nViatris agreed in October 2026 to acquire [Pacira Pharmaceuticals](https://akta.pro/company-profiles/0002kug/pacira-pharmaceuticals) for $1.65 billion, adding the pain therapy maker's products to its portfolio and expanding its innovative medicines business, Reuters reported. Viatris announced a tender offer for all Pacira shares at $36.50 per share in cash, expiring November 16, 2026, with Pacira's board unanimously recommending acceptance and the deal subject to a minimum condition of more than 50% share ownership, according to PR Newswire. Law firm Kahn Swick & Foti is investigating the proposed sale, seeking to determine whether the consideration and process are adequate or the offer undervalues the company, FinancialContent Business Page reported.\n\n## Viatris Cost Cuts and Leadership Changes\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Viatris announced in March 2026 a 10% global workforce reduction, up to 3,000 employees, expected to generate $600-700 million in annual savings as part of an enterprise-wide strategic review. The same records show the company announced in February 2026 the wind-down and closure of its Damastown manufacturing plant in Dublin, Ireland, affecting approximately 340 jobs, with production ending by the end of 2028. In May 2026, CFO Theodora 'Doretta' Mistras departed to join Edwards Lifesciences, and Chief Accounting Officer Paul Campbell was appointed interim CFO during the search for a permanent successor.\n\n## Viatris's Path From Generics to Complex Medicines\n\nViatris has been shifting from generics to complex generics and innovative treatments, having divested biosimilars and OTC portfolios, Labiotech.eu reported in October 2026. The company holds two late-stage assets, selatogrel and cenerimod, with phase 3 trials expected in 2027, according to the same report. In August 2026, Harrow entered an asset purchase agreement to acquire TYRVAYA nasal spray from Viatris for $100 million, MarketScreener reported.\n\n## Viatris Investor Events Ahead\n\nViatris said it will participate in fireside chats at three healthcare conferences: UBS Global Biopharma on November 17, Jefferies Global Healthcare on November 18, and Evercore Healthcare on December 1, 2026, PR Newswire reported. The Pacira tender offer expires November 16, 2026.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}